Study of Telatinib in Patients with Advanced Solid Tumors
Author Information
Author(s): Strumberg D, Schultheis B, Adamietz I A, Christensen O, Buechert M, Kraetzschmar J, Rajagopalan P, Ludwig M, Frost A, Steinbild S, Scheulen M E, Mross K
Primary Institution: University of Bochum (Marien Hospital, Herne), Herne, Germany
Hypothesis
The study aims to determine the maximum-tolerated dose and pharmacokinetics of telatinib in patients with advanced solid tumors.
Conclusion
Telatinib is safe and well tolerated up to a dose of 1500 mg BID continuous dosing, with some patients showing partial responses.
Supporting Evidence
- Hypertension (23%) and diarrhoea (7%) were the most frequent study drug-related adverse events.
- Two renal cell carcinoma patients reached a partial response.
- Telatinib was rapidly absorbed with a median tmax of 3 hours or less.
- The maximum-tolerated dose was not reached up to a dose of 1500 mg BID continuous dosing.
Takeaway
This study tested a new cancer drug called telatinib to see how much can be safely given to patients with tough-to-treat tumors, and it found that the drug is mostly safe and can help some patients.
Methodology
This was a multicentre, open-label, non-controlled, phase I dose escalation study.
Limitations
The study did not reach the maximum-tolerated dose, and the sample size may limit the generalizability of the findings.
Participant Demographics
71 patients (30 women, 41 men) with a median age of 60 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website